BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing and commercializing therapies for rare and serious diseases. Founded in 1997 and headquartered in San Rafael, California, the company specializes in treatments for conditions that often have limited or no available therapeutic options, including inherited metabolic disorders, skeletal diseases, and certain bleeding disorders.
BioMarin’s marketed products include Vimizim for mucopolysaccharidosis type IV A, Naglazyme for mucopolysaccharidosis type VI, Brineura for late-infantile neuronal ceroid lipofuscinosis type 2, Palynziq and Kuvan for phenylketonuria, and Voxzogo for achondroplasia in children with open growth plates. The company also markets Roctavian, a gene therapy for adults with severe hemophilia A, in certain markets. Its research and development programs continue to focus on genetic medicines, enzyme replacement therapies, and other treatments for rare diseases.
BioMarin serves patients and healthcare providers internationally, with commercial operations spanning North America, Europe, Latin America, and other global markets. Alexander Hardy has served as the company’s president and chief executive officer since 2023, bringing prior leadership experience from the biotechnology and pharmaceutical industry.
AI Generated. May Contain Errors.
